Abstract
The incidence of invasive breast cancer (IBC) can be dramatically reduced by improving our abilities to detect and treat ductal carcinoma in situ (DCIS). Progress will be based on a detailed understanding of molecular mechanisms responsible for tumor progression. An interesting study by Jang and colleagues evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1 and FGFR1) in large cohorts of pure DCIS, in the DCIS component of IBC, and in corresponding IBC. Of particular interest, they found a twofold increase in FGFR1 amplification in IBC versus pure DCIS, and significantly reduced disease-free survival in amplified versus unamplified IBC - leading the authors to conclude that FGFR1 plays an important role in the development and progression of IBC. These observations indeed provide hints that FGFR1 is important in this setting, although the issue is very complex and far from resolved.
Highlights
The incidence of invasive breast cancer (IBC) can be dramatically reduced by improving our abilities to detect and treat ductal carcinoma in situ (DCIS)
The incidence of IBC can be dramatically reduced by improving our abilities to detect and successfully treat DCIS, which will be based on a detailed understanding of molecular mechanisms responsible for tumor progression
There is much to learn, recent studies have begun to shed light on this important issue [5,6]. Among these is an interesting study by Jang and colleagues described in a recent issue of Breast Cancer Research, which evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1, and fibroblast growth factor receptor 1 (FGFR1)) in large cohorts of pure DCIS (n = 175), in the DCIS component of IBC (n = 203), and in the corresponding IBC (n = 427) [1]
Summary
The incidence of invasive breast cancer (IBC) can be dramatically reduced by improving our abilities to detect and treat ductal carcinoma in situ (DCIS). Among these is an interesting study by Jang and colleagues described in a recent issue of Breast Cancer Research, which evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1, and FGFR1) in large cohorts of pure DCIS (n = 175), in the DCIS component of IBC (n = 203), and in the corresponding IBC (n = 427) [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
